InsightfulValue
← Home

GlaxoSmithKline
GlaxoSmithKline

Pharma / Pharma and biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Infographic
Infographics
Overview
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of Β£34 billion and a net income of Β£5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
How to explain to a 10 year old kid about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

R2xheG9TbW l0aEtsaW5l LCBvciBHU0 sgZm9yIHNo b3J0LCBpcy BhIGJpZyBj b21wYW55IH RoYXQgaGVs cHMga2VlcC BwZW9wbGUg aGVhbHRoeS 4gVGhleSBj cmVhdGUgbW VkaWNpbmVz IGFuZCB2YW NjaW5lcywg d2hpY2ggYX JlIHNwZWNp YWwgc2hvdH MgdGhhdCBo ZWxwIHByZX ZlbnQgc2lj a25lc3MuIF lvdSBrbm93 IGhvdyBzb2 1ldGltZXMg eW91IG1pZ2 h0IGdvIHRv IHRoZSBkb2 N0b3IgYW5k IGdldCBhIG ZsdSBzaG90 PyBUaGF04o CZcyBhIHR5 cGUgb2Ygdm FjY2luZSwg YW5kIEdTSy BtYWtlcyBz b21lIG9mIH Rob3NlLjxi cj5HU0sgbW FrZXMgbW9u ZXkgYnkgc2 VsbGluZyB0 aGVzZSBtZW RpY2luZXMg YW5kIHZhY2 NpbmVzIHRv IGhvc3BpdG FscywgcGhh cm1hY2llcy wgYW5kIGRv Y3RvcnMgYW xsIGFyb3Vu ZCB0aGUgd2 9ybGQuIFdo ZW4gc29tZW 9uZSBpcyBz aWNrIGFuZC BuZWVkcyBt ZWRpY2luZS wgb3Igd2hl biBhIGNoaW xkIGdldHMg YSB2YWNjaW 5lIHRvIHN0 YXkgaGVhbH RoeSwgR1NL IGVhcm5zIG 1vbmV5LiBU aGV5IGFsc2 8gZG8gcmVz ZWFyY2ggdG 8gY3JlYXRl IG5ldyBtZW RpY2luZXMs IHdoaWNoIG NhbiBoZWxw IGV2ZW4gbW 9yZSBwZW9w bGUuIElmIH RoZXkgZGlz Y292ZXIgYS ByZWFsbHkg Z29vZCBuZX cgbWVkaWNp bmUsIHRoZX kgY2FuIHNl bGwgaXQgZm 9yIG1hbnkg eWVhcnMsIH doaWNoIGhl bHBzIHRoZW 0gbWFrZSBl dmVuIG1vcm UgbW9uZXku PGJyPk9uZS ByZWFzb24g R1NLIGlzIH N1Y2Nlc3Nm dWwgaXMgdG hhdCB0aGV5 IGZvY3VzIG EgbG90IG9u IHJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudC4gVGhp cyBtZWFucy B0aGV5IHNw ZW5kIHRpbW UgYW5kIG1v bmV5IHRvIG ZpbmQgbmV3 IGFuZCBiZX R0ZXIgd2F5 cyB0byB0cm VhdCBhbmQg cHJldmVudC BkaXNlYXNl cywgd2hpY2 ggbWFrZXMg cGVvcGxlIH RydXN0IHRo ZW0uIEFsc2 8sIGhlYWx0 aCBpcyBzdX BlciBpbXBv cnRhbnQsIH NvIHRoZXJl 4oCZcyBhbH dheXMgYSBu ZWVkIGZvci Bnb29kIG1l ZGljaW5lcy BhbmQgdmFj Y2luZXMuID xicj5JbiB0 aGUgZnV0dX JlLCBHU0sg d2lsbCBsaW tlbHkgc3Rh eSBzdWNjZX NzZnVsIGJl Y2F1c2UgcG VvcGxlIHdp bGwgYWx3YX lzIG5lZWQg aGVscCBzdG F5aW5nIGhl YWx0aHkuIE FzIG1vcmUg ZGlzZWFzZX MgbWF5IGNv bWUgdXAsIE dTSyB3aWxs IGtlZXAgdH J5aW5nIHRv IGZpbmQgbm V3IHdheXMg dG8gZmlnaH QgdGhlbS4g UGx1cywgdG hleSBhcmUg d29ya2luZy BvbiB0ZWNo bm9sb2d5IG FuZCBiZXR0 ZXIgd2F5cy B0byBkZWxp dmVyIG1lZG ljaW5lcywg c28gdGhleS BjYW4gaGVs cCBldmVuIG 1vcmUgcGVv cGxlLjxicj 4=
What is special about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

βœ… Download "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” totally free!

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=
What the company's business model?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu
Is AI a threat?
AI can indeed pose potential threats to GlaxoSmithKline (GSK) in various ways related to products, services, and competitive positioning:
1. Substitution: AI can enable the development of new pharmaceuticals or therapies that outperform existing GSK products. For example, AI-driven drug discovery processes can lead to faster identification of effective compounds, creating competition from companies that leverage these technologies successfully. If AI can produce superior treatment options, patients and healthcare providers may opt for alternatives instead of GSK’s offerings.
2. Disintermediation: AI could facilitate more direct relationships between patients and healthcare solutions, reducing the need for traditional pharmaceutical sales channels. The rise of telemedicine and AI-based diagnostics might enable patients to access personalized treatment plans directly, which could diminish GSK’s role as a traditional pharmaceutical provider and shift the focus toward tech-driven health solutions.
3. Margin Pressure: As AI enhances R&D efficiency and reduces costs for competitors, GSK may face margin pressures. Competitors using AI can develop and bring products to market more quickly and cost-effectively, allowing them to price their drugs more competitively. If GSK cannot match these efficiencies, it may need to lower its prices to retain market share, impacting profit margins.
In summary, while AI presents opportunities for GSK, it also poses significant risks in terms of substitution, disintermediation, and margin pressures that the company will need to navigate to maintain its competitive position.
Sensitivity to interest rates
The sensitivity of GlaxoSmithKline’s earnings, cash flow, and valuation to changes in interest rates can be analyzed through several key channels:
1. Cost of Debt: If interest rates rise, the cost of borrowing for GlaxoSmithKline may increase. This can lead to higher interest expenses, which can reduce net earnings. If the company has significant debt, even a small increase in rates can materially impact its earnings.
2. Discount Rate: Valuation models, such as discounted cash flow (DCF), use a discount rate that typically incorporates interest rates. An increase in interest rates raises the discount rate, which reduces the present value of future cash flows. As a result, the overall valuation of the company could decline.
3. Consumer Spending: Higher interest rates can lead to decreased consumer spending as borrowing becomes more expensive. This could affect GlaxoSmithKline’s sales, especially for over-the-counter products or consumer healthcare segments.
4. Research and Development: GlaxoSmithKline invests heavily in research and development. In a high-interest-rate environment, funding these projects through debt may become more costly, potentially leading to cuts in R&D budgets or delays in project timelines.
5. Portfolio Sensitivity: The specific product portfolio and pipeline developments of GlaxoSmithKline also play a role. If the company relies heavily on drugs with patent expirations or needs continuous investment for new products, changing interest rates may impact their financial strategies.
6. Investment and Expansion: Higher interest rates could dampen GlaxoSmithKline’s willingness or ability to invest in expansion, acquisitions, or new technologies, affecting long-term growth potential.
In summary, changes in interest rates can have multifaceted effects on GlaxoSmithKline’s earnings, cash flow, and valuation. Generally, rising interest rates pose risks due to increased borrowing costs and can lead to a lower valuation, while declining rates might provide a more favorable environment for the company’s financial performance.
Resilience to the future changes
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

QSByZWFsaX N0aWMgc2Nl bmFyaW8gdG hhdCBjb3Vs ZCBwZXJtYW 5lbnRseSBp bXBhaXIgR2 xheG9TbWl0 aEtsaW5l4o CZcyBlY29u b21pY3Mgb3 ZlciB0aGUg bmV4dCAz4o CTNSB5ZWFy cyBpcyB0aG UgbG9zcyBv ZiBleGNsdX Npdml0eSBm b3Igc2V2ZX JhbCBrZXkg cGF0ZW50cy wgbGVhZGlu ZyB0byBhIH NpZ25pZmlj YW50IGRlY2 xpbmUgaW4g cmV2ZW51ZS Bmcm9tIHNv bWUgb2YgaX RzIGJlc3Qt c2VsbGluZy Bwcm9kdWN0 cy4gVGhpcy BzY2VuYXJp byBjb3VsZC BiZSBleGFj ZXJiYXRlZC BieSBhIHJp c2UgaW4gY2 9tcGV0aXRp b24gZnJvbS BnZW5lcmlj IGRydWdzIG FuZCBiaW9z aW1pbGFycy wgcGFydGlj dWxhcmx5IG lmIHRoZXNl IGFsdGVybm F0aXZlcyBk ZW1vbnN0cm F0ZSBzaW1p bGFyIGVmZm ljYWN5IGF0 IGEgbXVjaC Bsb3dlciBj b3N0LiA8Yn I+QXMgcGF0 ZW50cyBleH BpcmUsIEdT SyBjb3VsZC BzZWUgYSBz aGFycCBkZW NsaW5lIGlu IHJldmVudW UgZnJvbSBp dHMgbGVhZG luZyB0aGVy YXBldXRpY3 MgYW5kIHZh Y2NpbmVzLC B3aGljaCBo aXN0b3JpY2 FsbHkgY29u dHJpYnV0ZS BhIHN1YnN0 YW50aWFsIH BvcnRpb24g b2YgaXRzIH NhbGVzLiBB ZGRpdGlvbm FsbHksIGlm IHRoZSBjb2 1wYW55IGZh Y2VzIGRpZm ZpY3VsdGll cyBpbiByZX BsZW5pc2hp bmcgaXRzIH Byb2R1Y3Qg cGlwZWxpbm Ugd2l0aCBp bm5vdmF0aX ZlIGRydWdz IG9yIHZhY2 NpbmVzIGR1 ZSB0byByZW d1bGF0b3J5 IGNoYWxsZW 5nZXMgb3Ig ZmFpbGVkIG NsaW5pY2Fs IHRyaWFscy wgdGhpcyBj b3VsZCBmdX J0aGVyIGRp bWluaXNoIG Z1dHVyZSBy ZXZlbnVlcy 4gPGJyPklu IHRoaXMgc2 NlbmFyaW8s IEdTS+KAmX MgbWFyZ2lu cyB3b3VsZC BsaWtlbHkg Y29udHJhY3 Qgc2lnbmlm aWNhbnRseS 4gVGhlIGNv bXBhbnkgbW F5IGhhdmUg dG8gZW5nYW dlIGluIGFn Z3Jlc3Npdm UgcHJpY2lu ZyBzdHJhdG VnaWVzIHRv IGNvbXBldG Ugd2l0aCBs b3dlci1jb3 N0IGFsdGVy bmF0aXZlcy wgd2hpY2gg d291bGQgc3 F1ZWV6ZSBw cm9maXQgbW FyZ2lucy4g VGhlIGNvbW JpbmVkIGVm ZmVjdCBvZi Bsb3dlciBy ZXZlbnVlIG FuZCByZWR1 Y2VkIG1hcm dpbnMgY291 bGQgbGVhZC B0byBhIHN1 YnN0YW50aW FsIGRlY3Jl YXNlIGluIG 9wZXJhdGlu ZyBpbmNvbW UsIGltcGFj dGluZyBjYX NoIGZsb3dz IG5lZ2F0aX ZlbHkuIExv d2VyIGNhc2 ggZmxvdyB3 b3VsZCByZX N0cmljdCBH U0vigJlzIG FiaWxpdHkg dG8gcmVpbn Zlc3QgaW4g cmVzZWFyY2 ggYW5kIGRl dmVsb3BtZW 50LCBwYXkg ZGl2aWRlbm RzLCBhbmQg cHVyc3VlIH N0cmF0ZWdp YyBhY3F1aX NpdGlvbnMu PGJyPk9uIH RoZSBiYWxh bmNlIHNoZW V0LCB0aGUg aW1wYWN0IH dvdWxkIGJl IHR3by1mb2 xkLiBGaXJz dCwgZGVjbG luaW5nIG9w ZXJhdGlvbm FsIHBlcmZv cm1hbmNlIG NvdWxkIGxl YWQgdG8gYS ByZWR1Y3Rp b24gaW4gcm V0YWluZWQg ZWFybmluZ3 MsIGRpbWlu aXNoaW5nIG 92ZXJhbGwg ZXF1aXR5Li BTZWNvbmQs IGlmIEdTSy BzZWVrcyB0 byBzaG9yZS B1cCByZXZl bnVlcyB0aH JvdWdoIGlu Y3JlYXNlZC Bib3Jyb3dp bmcgb3Igcm VzdHJ1Y3R1 cmluZyBhY3 Rpdml0aWVz LCBsaWFiaW xpdGllcyBt YXkgZ3Jvdy wgcmVzdWx0 aW5nIGluIG EgaGlnaGVy IGRlYnQtdG 8tZXF1aXR5 IHJhdGlvLi BGdXJ0aGVy bW9yZSwgaW YgdGhlIGNv bXBhbnkgaX MgdW5hYmxl IHRvIG1haW 50YWluIHN0 cm9uZyBjYX NoIHJlc2Vy dmVzLCBsaX F1aWRpdHkg cmF0aW9zIG NvdWxkIHdl YWtlbiwgbG VhZGluZyB0 byBjb25jZX JucyBhYm91 dCBzb2x2ZW 5jeS48YnI+ SW4gc3VtbW FyeSwgYSBw ZXJtYW5lbn QgaW1wYWly bWVudCBvZi BHbGF4b1Nt aXRoS2xpbm XigJlzIGVj b25vbWljcy BkdWUgdG8g cGF0ZW50IG V4cGlyYXRp b25zIGFuZC BmYWlsdXJl IHRvIGlubm 92YXRlIHdv dWxkIGxpa2 VseSBtYW5p ZmVzdCBpbi BzaWduaWZp Y2FudGx5IG xvd2VyIG1h cmdpbnMsIG RlY3JlYXNl ZCBjYXNoIG Zsb3csIGFu ZCBhIHN0cm FpbmVkIGJh bGFuY2Ugc2 hlZXQsIHJh aXNpbmcgY2 9uY2VybnMg YW1vbmcgaW 52ZXN0b3Jz IGFuZCBzdG FrZWhvbGRl cnMgYWJvdX QgdGhlIGNv bXBhbnnigJ lzIGxvbmct dGVybSB2aW FiaWxpdHku PGJyPg==
Interesting facts about the company
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 NTAgd2lkdG g9NTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TpSBHZXQg b3VyIGZyZW UgZUJvb2sg bm93OiA8aT 4iVGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrcyI8L2k+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvcD4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwhLS0K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGRpdiBz dHlsZT0nbW FyZ2luLXRv cDogMTJweD sgZm9udC1z aXplOiAxM3 B4OyBjb2xv cjogIzQ0ND snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgU2lnbiB1 cCBub3cgYW 5kIGdldCBv dXIgZnJlZS BlQm9vayAK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIDxi PlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3M8L2I+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxNnB4OyBm b250LXNpem U6IDE0cHg7 IGNvbG9yOi AjNDQ0OyBm b250LWZhbW lseTogLWFw cGxlLXN5c3 RlbSwgQmxp bmtNYWNTeX N0ZW1Gb250 LCBTZWdvZS BVSSwgUm9i b3RvLCBIZW x2ZXRpY2Eg TmV1ZSwgc2 Fucy1zZXJp ZjsgbGluZS 1oZWlnaHQ6 IDEuNjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgSG F2ZSB5b3Ug aGVhcmQgYW JvdXQgb3Vy IHNob3J0ID xzdHJvbmcg c3R5bGU9J2 ZvbnQtd2Vp Z2h0OiA2MD A7Jz5EYWls eSBWaWRlby BOZXdzbGV0 dGVyPC9zdH Jvbmc+Pwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naH R0cHM6Ly93 d3cuaW5zaW dodGZ1bHZh bHVlLmNvbS 9uZXdzbGV0 dGVyLnBocC cgdGFyZ2V0 PSdfYmxhbm snIHN0eWxl PSdjb2xvcj ogIzAwN0JG RjsgdGV4dC 1kZWNvcmF0 aW9uOiBub2 5lOyBmb250 LXdlaWdodD ogNTAwOyBt YXJnaW4tbG VmdDogNnB4 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgRm luZCBvdXQg bW9yZQogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgLS0+Ci AgICAgICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgIAog ICAgICAgIA ogICAgICAg IDxzcGFuIG NsYXNzPSdi bHVycmVkLX RleHQnPgog ICAgICAgIC AgICBNUzRn UjJ4aGVHID lUYldsMGFF dHMgYVc1bE lHbHpJRyBF Z1FuSnBkR2 x6IGFDQnRk V3gwYVcgNW hkR2x2Ym1G cyBJSEJvWV hKdFlXIE5s ZFhScFkyRn MgSUdOdmJY QmhibiBrc0 lIZHBkR2dn IGFHVmhaSE YxWVggSjBa WEp6SUdsdS BJRXh2Ym1S dmJpIHdnUl c1bmJHRnUg WkM0OFluSS tNaSA0Z1ZH aGxJR052IG JYQmhibmtn YUcgRnpJR0 VnYkc5dSBa eUJvYVhOMG IzIEo1TENC a1lYUnAgYm 1jZ1ltRmph eSBCMGJ5Qm hJSEJvIFlY SnRZV041SU cgOXdaVzVs WkNCaSBlU0 JLYjNObGNH IGdnVG1GMG FHRnUgSUds dUlFNWxkeS BCYVpXRnNZ VzVrIElHbH VJREU0TXog QXVQR0p5UG pNdSBJRlJv WlNCamIyID F3WVc1NUlI ZGggY3lCbW IzSnRZVyB4 c2VTQm1iM1 Z1IFpHVmtJ R2x1SUQgRT VNRFlnWW5r ZyBTbTl6Wl hCb0lFIFZr ZDJGeVpDQk 8gWVhSb1lX NGdZVyA1a0 lHaHBjeUJp IGNtOTBhR1 Z5TFcgbHVM V3hoZHl3Zy BWR2h2YldG eklFIGh2Yk d4dmQyRjUg TENCaGN5Qm hJSCBOdFlX eHNJSEJvIF lYSnRZV041 SUcgbHVJRX h2Ym1SdiBi aTQ4WW5JK0 5DIDRnVkdo bElHNWggYl dVZ1IyeGhl RyA4Z1kyOX RaWE1nIFpu SnZiU0IwYU cgVWdabWx5 YzNRZyBjSE p2WkhWamRD IEIwYUdGME lIUm8gWlNC amIyMXdZVy A1NUlIQnli MlIxIFkyVm tMQ0IzYUcg bGphQ0IzWV hNZyBZU0Jr Y21sbFpDIE J0YVd4cklI QnkgYjJSMV kzUWdZMiBG c2JHVmtJRW RzIFlYaHZM anhpY2ogND FMaUJIYkdG NCBieUJ0Wl hKblpXIFFn ZDJsMGFDQl ggWld4c1ky OXRaUyBCcG JpQXhPVGsx IElIUnZJR1 p2Y20gMGdS MnhoZUc4Zy BWMlZzYkdO dmJXIFVzSU hkb2FXTm8g SUhSb1pXNG diVyBWeVoy VmtJSGRwIG RHZ2dVMjFw ZEcgaExiR2 x1WlNCQyBa V1ZqYUdGdE lHIGx1SURJ d01EQWcgZE c4Z1ptOXli UyBCSGJHRj RiMU50IGFY Um9TMnhwYm 0gVXVQR0p5 UGpZdSBJRW RzWVhodlUy IDFwZEdoTG JHbHUgWlNC cGN5QmpkWC BKeVpXNTBi SGtnIGIyNW xJRzltSUgg Um9aU0JzWV hKbiBaWE4w SUhCb1lYIE p0WVdObGRY UnAgWTJGc0 lHTnZiWCBC aGJtbGxjeU JwIGJpQjBh R1VnZDIgOX liR1FzSUhk cCBkR2dnY2 1WMlpXIDUx WlNCdlppQn YgZG1WeUlD UTBNUyBCaW FXeHNhVzl1 IElHbHVJRE l3TWogQXVQ R0p5UGpjdS BJRlJvWlNC amIyIDF3WV c1NUlHbHog SUdFZ2JXRn FiMyBJZ2NI SnZaSFZqIF pYSWdiMlln ZG0gRmpZMm x1WlhNcyBJ R052Ym5OMW JXIFZ5SUdo bFlXeDAgYU dOaGNtVWdj SCBKdlpIVm pkSE1zIElH RnVaQ0J3Y2 0gVnpZM0pw Y0hScCBiMj RnYldWa2FX IE5wYm1Wek xDQmggYm1R Z2FYUWdhRy BGeklHRWdj SEpsIGMyVn VZMlVnYVcg NGdiM1psY2 lBeCBOVEFn WTI5MWJuIF J5YVdWekxq eGkgY2o0NE xpQkhiRyBG NGIxTnRhWF JvIFMyeHBi bVVnYUcgRn pJR0VnYkc5 dSBaeUJvYV hOMGIzIEo1 SUc5bUlITn AgWjI1cFpt bGpZVyA1ME lITmphV1Z1 IGRHbG1hV0 1nWVcgTm9h V1YyWlcxbC BiblJ6TENC cGJtIE5zZF dScGJtY2cg ZEdobElHUm xkbSBWc2Iz QnRaVzUwIE lHOW1JSFJ5 WlcgRjBiV1 Z1ZEhNZyBa bTl5SUVoSl ZpIHdnYVc1 bWJIVmwgYm 5waExDQmhi bSBRZ2JXRn NZWEpwIFlT NDhZbkkrT1 MgNGdWR2hs SUdOdiBiWE JoYm5rZ2FH IEZ6SUdGc2 MyOGcgWW1W bGJpQnBibi BadmJIWmxa Q0JwIGJpQn paWFpsY20g RnNJR2hwWj JndCBjSEp2 Wm1sc1pTIE JzWldkaGJD QmogWVhObG N5d2dhVyA1 amJIVmthVz VuIElHRWdK RE1nWW0gbH NiR2x2YmlC eiBaWFIwYk dWdFpXIDUw SUdadmNpQn AgYkd4bFoy RnNiSCBrZ2 NISnZiVzkw IGFXNW5JR0 5sY24gUmhh VzRnWkhKMS BaM01nWVc1 a0lHIEVnYz JWMGRHeGwg YldWdWRDQj NhWCBSb0lI Um9aU0JWIF V5Qm5iM1ps Y20gNXRaVz UwSUdadiBj aUFrTnpVd0 lHIDFwYkd4 cGIyNGcgWm 05eUlHMWhi biBWbVlXTj BkWEpwIGJt Y2dZVzVrSU ggRjFZV3hw ZEhrZyBZMj l1ZEhKdmJD IEJ3Y205aW JHVnQgY3lC aGRDQmhJSC BCc1lXNTBJ R2x1IElGQj FaWEowYnkg QlNhV052TG p4aSBjajR4 TUM0Z1NXID RnTWpBeU1D d2cgUjJ4aG VHOVRiVyBs MGFFdHNhVz VsIElHSmxZ MkZ0WlMgQj BhR1VnWm1s eSBjM1FnY0 doaGNtIDFo WTJWMWRHbG ogWVd3Z1ky OXRjRyBGdW VTQjBieUJ3 IGJHVmtaMl VnZEcgOGdi V0ZyWlNCcC BkSE1nWTJG eVltIDl1SU dadmIzUncg Y21sdWRDQn VaWCBRdGVt VnlieUJpIG VTQXlNRFV3 TGogeGljaj R4TVM0ZyBS MnhoZUc5VG JXIGwwYUV0 c2FXNWwgSU doaGN5QmhJ SCBOMGNtOX VaeUJqIGIy MXRhWFJ0Wl cgNTBJSFJ2 SUdOdiBjbk J2Y21GMFpT IEJ6YjJOcF lXd2cgY21W emNHOXVjMi BsaWFXeHBk SGtzIElIZH BkR2dnWVMg Qm1iMk4xY3 lCdiBiaUJw YlhCeWIzIF pwYm1jZ1oy eHYgWW1Gc0 lHaGxZVyB4 MGFDd2djbV ZrIGRXTnBi bWNnYVggUn pJR1Z1ZG1s eSBiMjV0Wl c1MFlXIHdn YVcxd1lXTj AgTENCaGJt UWdjMyBWd2 NHOXlkR2x1 IFp5QmpiMj F0ZFcgNXBk R2xsY3lCMy BhR1Z5WlNC cGRDIEJ2Y0 dWeVlYUmwg Y3k0OFluSS tNVCBJdUlG Um9aU0JqIG IyMXdZVzU1 SUcgaGhjeU JoSUdScCBk bVZ5YzJVZ2 QyIDl5YTJa dmNtTmwgTE NCM2FYUm9J RyA5MlpYSW dNVEF3IExE QXdNQ0JsYl ggQnNiM2xs WlhNZyBkMj l5YkdSM2FX IFJsSUdGdV pDQmggSUhO MGNtOXVaeS BCbWIyTjFj eUJ2IGJpQm thWFpsY24g TnBkSGtnWV c1ayBJR2x1 WTJ4MWMyIG x2YmlCcGJp QjAgYUdVZ2 QyOXlhMyBC c1lXTmxMan hpIGNqNHhN eTRnUjIgeG hlRzlUYlds MCBhRXRzYV c1bElHIGho Y3lCaElISn YgWW5WemRD QndhWCBCbG JHbHVaU0J2 IFppQnVaWG NnWkggSjFa M01nWVc1ay BJSFJ5WldG MGJXIFZ1ZE hNZ2FXNGcg WkdWMlpXeH ZjRyAxbGJu UXNJSGRwIG RHZ2diM1ps Y2kgQTFNQ0 JqWVc1ayBh V1JoZEdVZ2 RHIGhsY21G d2FXVnogSU dsdUlIWmhj bSBsdmRYTW djM1JoIFoy VnpJRzltSU cgTnNhVzVw WTJGcyBJSF J5YVdGc2N5 IDQ4WW5JK0 1UUXUgSUZS b1pTQmpiMi Axd1lXNTVJ R2hoIGN5Qm hJSE4wY20g OXVaeUJ3Y2 1WeiBaVzVq WlNCdmJpIE J6YjJOcFlX d2cgYldWa2 FXRXNJSCBk cGRHZ2diM1 psIGNpQTRO U3d3TUQgQW dabTlzYkc5 MyBaWEp6SU c5dUlGIFIz YVhSMFpYSW cgWVc1a0lH RmpkRyBsMl pTQmhZMk52 IGRXNTBjeU J2YmkgQk1h VzVyWldSSi BiaXdnUm1G alpXIEp2Yj Jzc0lHRnUg WkNCSmJuTj BZVyBkeVlX MHVQR0p5IF BqRTFMaUJI YkcgRjRiMU 50YVhSbyBT MnhwYm1VZ2 FHIEZ6SUhK bFkyVnAgZG 1Wa0lHNTFi VyBWeWIzVn pJR0YzIFlY SmtjeUJoYm 0gUWdjbVZq YjJkdSBhWF JwYjI0Z1pt IDl5SUdsMG N5QjMgYjNK ckxDQnBibS BOc2RXUnBi bWNnIFltVn BibWNnYm0g RnRaV1FnYj I1bCBJRzlt SUhSb1pTIE RpZ0p4WGIz SnMgWk9LQW 1YTWdUVyA5 emRDQkZkR2 hwIFkyRnNJ RU52YlggQm hibWxsYytL QSBuU0JpZV NCMGFHIFVn UlhSb2FYTn cgYUdWeVpT QkpibiBOMG FYUjFkR1Vn IFptOXlJRE V4SUcgTnZi bk5sWTNWMC BhWFpsSUhs bFlYIEp6TG c9PQogICAg ICAgIDwvc3 Bhbj4KICAg ICAgICAKIC AgICAgICA=
See Company Q&A
GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

βœ… Download "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” totally free!

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal